David Wiersema, DO
Physical Medicine & Rehabilitation · Saginaw, MINPI 1851322549
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 84.1% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2024 at $6,432 and has fallen 72.2% since, to $1,790 in 2025. Among physical medicine & rehabilitation clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 248 payments — averaging $68.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$14K
- Neurocrine Biosciences, Inc.$928
- Idorsia Pharmaceuticals US Inc$227
- Eisai Inc.$184
- Amgen$182
- Avanir Pharmaceuticals, Inc.$139
- plus $1K from 28 others
What the payments were for
- Speaking & faculty fees$9,40055%
- Travel & lodging$2,09212%
- Food & beverage$5,48032%
- Education$140%
- Gifts$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 119 | $14,314 |
| Neurocrine Biosciences, Inc. | 36 | $928 |
| Idorsia Pharmaceuticals US Inc | 11 | $227 |
| Eisai Inc. | 3 | $184 |
| Amgen | 11 | $182 |
| Avanir Pharmaceuticals, Inc. | 9 | $139 |
| Radius Health, Inc. | 8 | $121 |
| Abbott | 3 | $68 |
| Pfizer | 4 | $65 |
| Exact Sciences | 3 | $65 |
| UCB, Inc. | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 2 | $53 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Merz Pharmaceuticals, LLC | 3 | $48 |
| Biodelivery Sciences International, Inc. | 3 | $48 |
| Lundbeck LLC | 3 | $47 |
| Ipsen Biopharmaceuticals, Inc | 2 | $45 |
| Lilly USA, LLC | 3 | $42 |
| Antares Pharma, Inc. | 2 | $40 |
| Merck | 2 | $35 |
| Saol Therapeutics Inc. | 2 | $33 |
| Electronic Waveform Lab, Inc. | 1 | $31 |
| GSK | 1 | $21 |
| Novo Nordisk | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Alvogen Inc | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Tolmar, Inc. | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Medtronic | 1 | $15 |
| Novartis | 1 | $13 |
| Redhill Biopharma Inc. | 1 | $12 |
| Merz North America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,019 in reported general payments places this provider in the 95th percentile of 469 physical medicine & rehabilitation providers in Michigan.
See all physical medicine & rehabilitation providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ForteoTeriparatide | 11 | $49,320 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,049 |
| Baclofen | 58 | $1,187 |
| Gabapentin | 24 | $323 |
| Oxycodone Hcl | 13 | $166 |
| Trazodone Hcl | 12 | $118 |
| Pregabalin | 15 | $110 |
| Tramadol Hcl | 25 | $64 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo | $42 | $49,32011 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $18 | $6,04913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 469 physical medicine & rehabilitation providers in Michigan.
Other physical medicine & rehabilitation in Saginaw
- Daniel DuffySaginaw$3K
- Edward DabrowskiRoseville$167K
- Erika ErlandsonAnn Arbor$54K
- Gianna Maria RodriguezAnn Arbor$41K
- Mathew SaffarianEast Lansing$24K
- Jason PeterTroy$20K
- Satyum ParikhWarren$11K
- Reginald KapteynMuskegon$11K
- Emily GladstoneGrand Rapids$10K
- In YoonDearborn$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.